Transtoxbio-DART
  • Home
  • Transtoxbio-DART

Transtoxbio

Transcell Biologics has pioneered an innovative and revolutionary animal-free testing strategy (patent protected) to implement as Digital Animal Replacement Technology (DART) – An Enterprise Solution. This technology is designed to be easily adopted by global bio/pharma companies at various stages of their discovery and development functions. It aligns with the recent FDA Modernization Act 2.0 and the international ban on testing cosmetics on animals, encouraging the use of non-animal cruelty-free testing platform

  • The use of AI/ML-powered digital workstations with prediction models to automate safety or efficacy tests
  • Stem cell-based MicroPhysiological in vitro systems that produce human-relevant readouts as clinical surrogate data points when treated with test agents
  • Integration into the end-user’s existing workflows to support discovery, development, and manufacturing processes
  • Benefits such as phasing out animal testing protocols and building a brand as an ethical organization
  • Alignment with the 3Rs in animal testing (Replace, Reduce, Refine)
  • Assays offered as modules under a single Application Programming Interface
Download Brochure
DART An Animal-Free Testing Alternative
DART: Upholding the Principles of 3Rs—Replacement, Reduction, and Refinement

Backed by Transcell Biologics breakthrough scientific innovation in animal-free testing strategy, Quantiphi, with strategic partnerships with technology leaders such as Google Cloud, Amazon Web Services, and NVIDIA, combined with its commitment to HIPAA compliance and ethical AI solutions, ensures that its practices are cutting-edge and compliant with industry standards